Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Cash from Financing Activities (2016 - 2019)

Alterity Therapeutics' quarterly Cash from Financing Activities came in at $166760.3 in Q4 2019, up 62.62% year-on-year from $102549.0 in Q4 2018, and up 62.62% quarter-over-quarter from $102549.0 in Q4 2018.

Alterity Therapeutics has reported Cash from Financing Activities for 4 years, with the latest figure at $166760.3 in Q4 2019.

  • For the quarter ending Q4 2019, Cash from Financing Activities rose 62.62% year-over-year to $166760.3; the trailing twelve-month figure through Dec 2019 stood at $124416.7 (changed N/A YoY), and the FY2025 full-year result was $25.4 million, up 318.28% from the prior year.
  • Cash from Financing Activities for Q4 2019 stood at $166760.3, up from $102549.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $166760.3 in Q4 2019, with the low at -$115796.0 in Q4 2016.
  • Average Cash from Financing Activities over 4 years is $31104.2, with a median of $36726.2 recorded in 2017.
  • Year-over-year, Cash from Financing Activities soared 452.44% in 2018 and jumped 62.62% in 2019.
  • Tracing ATHE's Cash from Financing Activities over 4 years: stood at -$115796.0 in 2016, then soared by 74.87% to -$29096.6 in 2017, then soared by 452.44% to $102549.0 in 2018, then soared by 62.62% to $166760.3 in 2019.
  • The last three Cash from Financing Activities figures came in at $166760.3 (Q4 2019), $102549.0 (Q4 2018), and -$29096.6 (Q4 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 7.00 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 53,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -538.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -802.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 15.71 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - 238.74 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 166,760.26
Dec 31, 2019 166,760.26
Dec 31, 2018 102,548.96
Dec 31, 2018 102,548.96
Dec 31, 2017 -29,096.57
Dec 31, 2017 -29,096.57
Dec 31, 2016 -115,795.95
Dec 31, 2016 -115,795.95